Abstract
Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients with BRCA-mutated ovarian cancer who have been treated with two or more lines of chemotherapy. Rucaparib is also approved in the USA and the EU for use as maintenance therapy in adult patients with recurrent or relapsed ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Based on an analysis of patients across two phase II clinical trials, rucaparib displayed clinical activity as third- (or later-) line treatment of BRCA-mutated ovarian cancer, with rucaparib-treated patients having a confirmed objective response rate of 54%. Furthermore, as demonstrated in the randomized, placebo-controlled, phase III ARIEL3 trial, rucaparib significantly improved progression-free survival when used as maintenance treatment in patients with platinum-sensitive ovarian cancer. Rucaparib had an acceptable tolerability profile in clinical trials in women with ovarian cancer. Common adverse events were generally manageable with dose modification and/or supportive care. Thus, currently available data indicate that rucaparib is a useful addition to the options available to clinicians for the treatment of advanced ovarian cancer, in both the treatment and maintenance therapy settings.
Similar content being viewed by others
References
International Agency for Research on Cancer. Cancer Today; 2019. http://gco.iarc.fr/today/home. Accessed 22 Jan 2019.
Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 2.2018); 2018. http://www.nccn.org. Accessed 07 Feb 2019.
Schreiber V, Dantzer F, Amé J-C, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517–28.
Boehler C, Gauthier LR, Mortusewicz O, et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA. 2011;108(7):2783–8.
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.
Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–98.
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.
US FDA. Rubraca® (rucaparib) tablets: US prescribing information. 2018. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf. Accessed 26 Feb 2019.
European Commission. Rubraca: summary of product characteristics. 2019. http://www.ema.europa.eu/documents/product-information/rubraca-epar-product-information_en.pdf. Accessed 26 Feb 2019.
Robillard L, Nguyen M, Harding TC, et al. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib [abstract no. 2475]. Cancer Res. 2017;77(13 Suppl):2475.
Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–30.
Murai J, Huang S-YN, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.
Drew Y, Mulligan EA, Vong W-T, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–46.
Ihnen M, zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12(6):1002–15.
Murray J, Thomas H, Berry P, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110(8):1977–84.
Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095–106.
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.
Shroff RT, Hendifar A, McWilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol. 2018. https://doi.org/10.1200/po.17.00316.
Falzacappa MVV, Ronchini C, Faretta M, et al. The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol Cancer Ther. 2015;14(4):889–98.
Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103(10):1588–96.
Nile DL, Rae C, Hyndman IJ, et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16:621.
Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–7.
Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984–98.
Wang Y-T, Yuan B, Chen H-D, et al. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci. 2018;109(3):821–31.
McCormick A, Donoghue P, Dixon M, et al. Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparib. Clin Cancer Res. 2017;23(8):2050–60.
Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37–46.
Shapiro GI, Kristeleit RS, Burris HA, et al. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2018;8(1):107–18.
Wilson RH, Evans TRJ, Middleton MR, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017;116(7):884–92.
Xiao JJ, Green M, Ma S, et al. Population pharmacokinetics (PK) of rucaparib (CO-338) in patients with advanced ovarian cancer (AOC) or other solid tumors [abstract no. PII-144]. Clin Pharmacol Ther. 2017;101(Suppl. 1):S92.
Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58–65.
Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.
Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891–925.
Heo Y-A, Duggan ST. Niraparib: a review in ovarian cancer. Target Oncol. 2018;13(4):533–9.
Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015;29(2):143–50.
Ledermann J, Sessa C, Colombo N. eUpdate—ovarian cancer treatment recommendations; 2016. http://www.esmo.org/Guidelines/Gynaecological-Cancers/Newly-Diagnosed-and-Relapsed-Epithelial-Ovarian-Carcinoma/eUpdate-Treatment-Recommendations. Accessed 07 Feb 2019.
Acknowledgements
During the peer review process, the manufacturer of rucaparib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information
The manuscript was reviewed by:M.C. Cristea, Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA; S. Ferrero, Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico, San Martino, Genoa, Italy; M. Markman, Eastern Regional Medical Center, Cancer Treatment Centers of America, Philadelphia, PA, USA.
Rights and permissions
About this article
Cite this article
Shirley, M. Rucaparib: A Review in Ovarian Cancer. Targ Oncol 14, 237–246 (2019). https://doi.org/10.1007/s11523-019-00629-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-019-00629-5